Skip to main content

Advertisement

SpringerLink
Go to cart
Book cover

Pharmacovigilance in the European Union pp 45–102Cite as

  1. Home
  2. Pharmacovigilance in the European Union
  3. Chapter
Practical Implementation in Six Member States

Practical Implementation in Six Member States

  • Michael Kaeding4,
  • Julia Schmälter4 &
  • Christoph Klika4 
  • Chapter
  • Open Access
  • First Online: 21 February 2017
  • 3414 Accesses

Abstract

This chapter represents the core of this study and presents the main findings. The aim of this chapter is threefold. First, it offers in-depth explanations of the adverse drug reaction (ADR) reporting systems, and it describes relevant tasks and actors involved in all six countries under consideration (the United Kingdom, Finland, Poland, France, Portugal and Germany).

Keywords

  • Healthcare Professional
  • Competent Authority
  • Batch Number
  • Awareness Raising
  • Pharmacovigilance System

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Download chapter PDF

References

  • ANSM (2016). Annual Report 2015. Last accessed on 04.11.2016: ansm.sante.fr/content/download/97375/1237039/…/ANSM-RA-15_EN_oct2016.pdf

    Google Scholar 

  • AkdÄ (2016). Tätigkeitsbericht 2015. Last accessed on 02.12.2016: www.akdae.de/Kommission/Organisation/Aufgaben/Taetigkeitsbericht.pdf

  • Bronder, E., Stammschulte, T. (2013). Nebenwirkungen von Arzneimitteln: Meldung an die Arzneimittelkommission der deutschen Ärzteschaft, Erfassung in einer Datenbank und Bewertung. Ärzteblatt Thüringen, Ausgabe 12/2013: 670-672.

    Google Scholar 

  • Caron, J., Gautier, S., Mallaret, M. (2014). Spontaneous Reporting: France. Andrews, E., Moore, N. (eds) (2014). Mann’s Pharmacovigilance. Wiley-Blackwell.

    Google Scholar 

  • Casassus, B. (2016). Drug Scandals in France: Have the Lessons Been Learnt? The Lancet 2016/388: 550-552.

    Google Scholar 

  • Duarte, M., Ferreira, P., Soares, M., Cavaco, A., Martins, A. P. (2015). Community Pharmacists’ Attitudes towards Adverse Drug Reaction Reporting and their Knowledge of the New Pharmacovigilance Legislation in the Southern Region of Portugal: A Mixed Methods Study. Drugs and Therapy Perspectives 31 (9): 316-322.

    Google Scholar 

  • EMA (2013). Medication Errors Workshop – Workshop Report. EMA/144458/2013 Patient Health Protection 06.05.2013.

    Google Scholar 

  • Fimea (2010). Guideline 2/2010 – Reporting of Adverse Drug Reactions. Last accessed on 22.05.2016: https://www.fimea.fi/documents/542809/844142/17296_Ohje_2_2010_Haittavaikutusten_ilmoittaminen_EN.pdf.

  • Fimea Administrative Guidelines 2/2013 (2013). Reporting of Adverse Drug Reactions, 3428/03.01.01/2012. Last accessed on 22.05.2016: https://www.fimea.fi/…/23514_Ohje_2_2013_EN.pdf

  • Finnish Communicable Diseases Act (583/1986). Last accessed on 22.05.2016: www.finlex.fi/fi/laki/kaannokset/1986/en19860583.pdf

  • Foy, M. (2015). eHealth – The Road towards More Efficient and Integrated Care Solutions for Patients. Presentation for MHRA.

    Google Scholar 

  • Hagemann, U., Paeschke, N. (2014). How Pharmacovigilance Is Organised in Germany. In: Andrews, E., Moore, N. (eds) (2014). Mann’s Pharmacovigilance. Wiley-Blackwell Oxford.

    Google Scholar 

  • Inácio, P., Airaksinen, M., Cavaco, A. (2015). Language Does Not Come “in Boxes”: Assessing Discrepancies between Adverse Drug Reactions Spontaneous Reporting and MedDRA® Codes in European Portuguese. Research in Social and Administrative Pharmacy 11: 664-674.

    Google Scholar 

  • INFARMED (2011). Boletim de Farmacovigilânica. Boletim de Farmacovigilância 15 (2).

    Google Scholar 

  • INFARMED (2016). Boletim de Farmacovigilânica. Boletim de Farmacovigilância 20 (2).

    Google Scholar 

  • Marques, J. I. O., Polonia, J. M. J., Figueiras, A. G., Santos, C. M., Herdeiro, M. F. (2016). Nurses’ Attitudes and Spontaneous Adverse Drug Reaction Reporting: A Case-Control Study in Portugal. Journal of Nursing Management 24: 409-416.

    Google Scholar 

  • Matos, C., Van Hunsel, F., Joaquim, J. (2015). Are Consumers Ready to Take Part in the Pharmacovigilance System? A Portuguese Preliminary Study Concerning ADR Reporting. European Journal of Clinical Pharmacology 71: 883-890.

    Google Scholar 

  • Mendes, D., Alves, C., Batel-Marques, F. (2014). Safety Profiles of Adalimumab, Etanercept and Infliximab: A Pharmacovigilance Study Using a Measure of Disproportionality in a Database of Spontaneously Reported Adverse Events. Journal of Clinical Pharmacy and Therapeutics 39: 307-313.

    Google Scholar 

  • MHRA (2016). Guidance on Adverse Drug Reactions. Last accessed on 13.09.2016: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/403098/Guidance_on_adverse_drug_reactions.pdf

  • Mullard, A. (2011). Mediator Scandal Rocks French Medical Community. The Lancet 2011/377: 890-892.

    Google Scholar 

  • Ribeiro-Vaz, I., Santos, C., Cruz-Correira, R. (2016). Promoting Adverse Drug Reaction Reporting: Comparison of Different Approaches. Revista Saúde Pública 50 (14): 1-9.

    Google Scholar 

  • Santos, A. (n.d.). Direct Patient Reporting in the European Union: A Snapshot of Reporting Systems in Seven Member States. Health Action International. Last accessed on 02.12.2016: http://haiweb.org/publication/direct-patient-reporting-in-the-eu-a-snapshot-of-reporting-systems-in-seven-member-states/

  • THL (2016). National Institute for Health and Welfare – Vaccinations. Last accessed on 04.10.2016: https://www.thl.fi/fi/web/thlfi-en/statistics/information-on-statistics/quality-descriptions/vaccinations

  • URPL (2015). Jak zgłaszać działania niepożądane (How to Report Side Effects). On Youtube posted by URPLWMiPB on 10.02.2015. Last accessed on 25.09.2016: https://www.youtube.com/watch?v=mE_EbeE7ado&feature=youtu.be

  • URPL (2014). Zgłaszanie działań niepożądanych (Reporting Adverse Events). On Youtube posted by URPLWMiPB on 14.02.2014. Last accessed on 25.09.2016: https://www.youtube.com/watch?v=g2H8BOq0UOc

  • Yellow Card Centre Wales (n.d.). Annual Report Year 2013-2014. Last accessed 13.09.2016: http://www.yellowcardwales.org/pdfs/YCCW%20Annual%20Report%202013-14-%20Final.pdf

Download references

Author information

Authors and Affiliations

  1. Institut für Politikwissenschaft, Universität Duisburg-Essen Institut für Politikwissenschaft, Duisburg, Germany

    Michael Kaeding, Julia Schmälter & Christoph Klika

Authors
  1. Michael Kaeding
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia Schmälter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christoph Klika
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Kaeding .

Rights and permissions

This chapter is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.

Copyright information

© 2017 The Author(s)

About this chapter

Cite this chapter

Kaeding, M., Schmälter, J., Klika, C. (2017). Practical Implementation in Six Member States. In: Pharmacovigilance in the European Union. Springer, Wiesbaden. https://doi.org/10.1007/978-3-658-17276-3_5

Download citation

  • .RIS
  • .ENW
  • .BIB
  • DOI: https://doi.org/10.1007/978-3-658-17276-3_5

  • Published: 21 February 2017

  • Publisher Name: Springer, Wiesbaden

  • Print ISBN: 978-3-658-17275-6

  • Online ISBN: 978-3-658-17276-3

  • eBook Packages: Political Science and International StudiesPolitical Science and International Studies (R0)

Share this chapter

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Over 10 million scientific documents at your fingertips

Switch Edition
  • Academic Edition
  • Corporate Edition
  • Home
  • Impressum
  • Legal information
  • Privacy statement
  • Your US state privacy rights
  • How we use cookies
  • Your privacy choices/Manage cookies
  • Accessibility
  • FAQ
  • Contact us
  • Affiliate program

Not affiliated

Springer Nature

© 2023 Springer Nature Switzerland AG. Part of Springer Nature.